Articles published in Journal of Multiple Sclerosis have been cited by esteemed scholars and scientists all around the world. Journal of Multiple Sclerosis has got h-index 11, which means every article in Journal of Multiple Sclerosis has got 11 average citations.
Following are the list of articles that have cited the articles published in Journal of Multiple Sclerosis.
Journal of Multiple Sclerosis has got h-index 11, which means every article in Journal of Multiple Sclerosis has got 11 average citations.Following are the list of articles that have cited the articles published in Journal of Multiple Sclerosis.
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total published articles |
50 | 59 | 6 | 3 | 9 |
Conference proceedings |
0 | 0 | 0 | 0 | 0 |
Citations received as per Google Scholar, other indexing platforms and portals |
54 | 59 | 46 | 57 | 43 |
Journal total citations count | 521 |
Journal impact factor | 2.30 |
Journal 5 years impact factor | 2.28 |
Journal cite score | 1.96 |
Journal h-index | 11 |
Journal h-index since 2019 | 9 |
Journal Impact Factor 2020 formula |
IF= Citations(y)/{Publications(y-1)+ Publications(y-2)} Y= Year |
Journal 5-year Impact Factor 2020 formula |
Citations(2016 + 2017 + 2018 + 2019 + 2020)/ {Published articles(2016 + 2017 + 2018 + 2019 + 2020)} |
Journal CiteScore |
CiteScorey = Citationsy + Citationsy-1 + Citationsy-2 + Citations y-3 / Published articlesy + Published articlesy-1 + Published articlesy-2 + Published articles y-3 |
Y?lmaz, V., Tura, D. A., Ulusoy, C., Ya?argün, D. Ö., Ç?nar, S. A., & Türko?lu, R. (2017). Flow cytometry analysis of peripheral blood B cell distribution of patients with multiple sclerosis. Turk J Neurol, 23, 219-224. |
|
Mazdeh, M., Moradi, N., Khoshroo, E., Shayesteh, Z., Taheri, M., Sayad, A., ... & Solgi, G. (2018). Down-regulation of TYK2, CBLB and LMP7 genes expression in relapsing-remitting multiple sclerosis patients treated with interferon-beta. Journal of neuroimmunology, 314, 24-29. |
|
Karim, M. R., & Wang, Y. F. (2016). The study progress of B cells and neuroimmunological diseases. J Neurol Neurophysiol, 7(2), 369. |
|
Lim, Z. W., Elwood, E., Naveed, H., & Galea, I. (2016). Lymphopenia in treatment-naive relapsing multiple sclerosis. Neurology-Neuroimmunology Neuroinflammation, 3(5). |
|
Melero-Jerez, C., Alonso-Gómez, A., Moñivas, E., Lebrón-Galán, R., Machín-Díaz, I., de Castro, F., & Clemente, D. (2020). The proportion of myeloid-derived suppressor cells in the spleen is related to the severity of the clinical course and tissue damage extent in a murine model of multiple sclerosis. Neurobiology of disease, 140, 104869. |
|
Severa, M., Zhang, J., Giacomini, E., Rizzo, F., Etna, M. P., Cruciani, M., ... & Coccia, E. M. (2019). Thymosins in multiple sclerosis and its experimental models: Moving from basic to clinical application. Multiple sclerosis and related disorders, 27, 52-60. |
|
Deng, J., Pennati, A., Cohen, J. B., Wu, Y., Ng, S., Wu, J. H., ... & Galipeau, J. (2016). GIFT4 fusokine converts leukemic B cells into immune helper cells. Journal of translational medicine, 14(1), 1-12. |
|
Aktura, ?. D., Y?lmaz, V., Özkan-Ya?argün, D., Ulusoy, C., Tüzün, E., & Türko?lu, R. (2018). Peripheral blood memory B cell frequency predicts conversion from clinically isolated syndrome to multiple sclerosis. Multiple sclerosis and related disorders, 23, 9-14. |
|
Karim, M. R., & Wang, Y. F. (2019). Phenotypic identification of CD19+ CD5+ CD1d+ regulatory B cells that produce interleukin 10 and transforming growth factor ?1 in human peripheral blood. Archives of medical science: AMS, 15(5), 1176. |
|
Cho, E. B., Cho, H. J., Seok, J. M., Min, J. H., Kang, E. S., & Kim, B. J. (2018). The IL-10-producing regulatory B cells (B10 cells) and regulatory T cell subsets in neuromyelitis optica spectrum disorder. Neurological Sciences, 39(3), 543-549. |
|
Li, H., Deng, Y., Liang, J., Huang, F., Qiu, W., Zhang, M., ... & Zheng, S. G. (2019). Mesenchymal stromal cells attenuate multiple sclerosis via IDO-dependent increasing the suppressive proportion of CD5+ IL-10+ B cells. American journal of translational research, 11(9), 5673. |
|
Alexopoulos, H., Biba, A., & Dalakas, M. C. (2016). Anti-B-cell therapies in autoimmune neurological diseases: rationale and efficacy trials. Neurotherapeutics, 13(1), 20-33. |
|
Giacomini, E., Rizzo, F., Etna, M. P., Cruciani, M., Mechelli, R., Buscarinu, M. C., ... & Severa, M. (2018). Thymosin-?1 expands deficient IL-10-producing regulatory B cell subsets in relapsing–remitting multiple sclerosis patients. Multiple Sclerosis Journal, 24(2), 127-139. |
|
Karim, M. R., Zhang, H. Y., Yuan, J., Sun, Q., & Wang, Y. F. (2017). Regulatory B cells in seropositive myasthenia gravis versus healthy controls. Frontiers in neurology, 8, 43. |
|
Abbasifard, M., & Khorramdelazad, H. (2020). The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics. Life sciences, 118097. |
|
Pennati, A., Ng, S., Wu, Y., Murphy, J. R., Deng, J., Rangaraju, S., ... & Galipeau, J. (2016). Regulatory B cells induce formation of IL-10-expressing T cells in mice with autoimmune neuroinflammation. Journal of Neuroscience, 36(50), 12598-12610. |
|
Staun-Ram, E., & Miller, A. (2017). Effector and regulatory B cells in multiple sclerosis. Clinical immunology, 184, 11-25. |
|
Freiesleben, S., Hecker, M., Zettl, U. K., Fuellen, G., & Taher, L. (2016). Analysis of microRNA and gene expression profiles in multiple sclerosis: integrating interaction data to uncover regulatory mechanisms. Scientific reports, 6(1), 1-14. |
|
Agius, M. A., Klodowska-Duda, G., Maciejowski, M., Potemkowski, A., Li, J., Patra, K., ... & Flor, A. (2019). Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study. Multiple Sclerosis Journal, 25(2), 235-245. |
|
Claes, N., Fraussen, J., Stinissen, P., Hupperts, R., & Somers, V. (2015). B cells are multifunctional players in multiple sclerosis pathogenesis: insights from therapeutic interventions. Frontiers in immunology, 6, 642. |
|